+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Immunosuppressants Market by Drug class, Calcineurin Inhibitors, Indication, and Distribution channel: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5021783
  • Report
  • January 2020
  • Region: Global
  • 165 Pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Bristol Myers Squibb
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • Mylan Laboratories Inc.
The global immunosuppressants market was valued at $13,890.0 million in 2018 and is expected to reach $42,511.37 million by 2026, registering a CAGR of 14.7% from 2019 to 2026. Immunosuppressants suppress the immune response or agents after organ transplantation or grafting procedures. After an organ transplantation, recipient’s body produces certain immune response against it as it considers the organ as an antigen that may harm the body. These immunosuppressants help in combating hyper immune response produced by body’s immune cells. These drugs are a crucial part of organ transplantation procedure as it prevents the body from serious damages.



Increase in incidence of autoimmune disorders such as arthritis, multiple sclerosis, and alopecia areata is the major factor that drives the market growth. In addition, surge in organ transplant procedures such as kidney transplant and liver transplant due to rise in incidence of organ failure further propels the market growth. For instance, as per the U.S. Government Information on Organ Donation and Transplantation, 36,528 organ transplants were performed in 2018 in the country. However, dearth of availability of organ donors and high cost of transplantation as well as immunosuppressant drugs are the limitations for the growth of this market. In addition, side effects of these drugs are expected to hamper the market growth. One of the major side effects of these drugs, especially, corticosteroids is osteoporosis. It is the condition in which density of bones is decreased, increasing the risk of fractures. Any bone in the body can be affected; however, fractures are most commonly seen in the hip, spine, or wrist. On the contrary, increase in use of tissue engineering for generation of implants provides growth opportunities for this market. In addition, rise in disposable income in developing economies, surge in awareness among individuals towards organ donation is anticipated to create lucrative opportunities in the near future.

The market is segmented on the basis of drug class, indication, distribution channel, and region. By drug class, it is divided into corticosteroids, monoclonal antibodies, calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, and others. On the basis of indication, it is categorized into organ transplantation, autoimmune disorders, and non-autoimmune inflammatory diseases. By distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
  • Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Drug Class
  • Corticosteroids
  • Monoclonal Antibodies (mAbs)
  • Calcineurin Inhibitors
  • mTOR Inhibitors
  • Anti-Proliferative Agents
  • Others

By Indication
  • Organ Transplantation
  • Autoimmune Disorders
  • Non-Autoimmune Inflammatory Diseases

By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY PLAYERS
  • Astellas Pharma, Inc.
  • Bristol Myers Squibb
  • AbbVie Inc.
  • GlaxoSmithKline Plc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mylan Laboratories Inc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A
Frequently Asked Questions about the Global Immunosuppressants Market

What is the estimated value of the Global Immunosuppressants Market?

The Global Immunosuppressants Market was estimated to be valued at $13890.0 million in 2018.

What is the growth rate of the Global Immunosuppressants Market?

The growth rate of the Global Immunosuppressants Market is 15.0%, with an estimated value of $42511.4 million by 2026.

What is the forecasted size of the Global Immunosuppressants Market?

The Global Immunosuppressants Market is estimated to be worth $42511.4 million by 2026.

Who are the key companies in the Global Immunosuppressants Market?

Key companies in the Global Immunosuppressants Market include Astellas Pharma Inc., Bristol Myers Squibb, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Mylan Laboratories Inc., Novartis AG and Sanofi S.A..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Bristol Myers Squibb
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • Mylan Laboratories Inc.

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Porter's Five Forces Analysis
3.3.1. Moderate Bargaining Power of Buyers
3.3.2. Low Bargaining Power of Suppliers
3.3.3. Moderate Threat of Substitutes
3.3.4. Low Threat of New Entrants
3.3.5. Moderate Competitive Rivalry
3.4. Top Player Positioning
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Surge In Autoimmune Disorders
3.5.1.2. Increase In Demand For Organ Transplantation
3.5.2. Restraint
3.5.2.1. Lack of Awareness Towards Organ Transplantation
3.5.3. Opportunity
3.5.3.1. Various Growth Opportunities In Emerging Economies
Chapter 4: Immunosuppressant Market, By Indication
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Organ Transplantation
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Share Analysis, By Country
4.3. Autoimmune Disorders
4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Share Analysis, By Country
4.4. Other Diseases
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Share Analysis, By Country
Chapter 5: Immunosuppressant Market, By Drug Class
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Calcineurin Inhibitors
5.2.1. Market Size And Forecast
5.2.2. Market Share Analysis, By Country
5.3. Corticosteroids
5.3.1. Market Size And Forecast
5.3.2. Market Share Analysis, By Country
5.4. Monoclonal Antibodies (Mabs)
5.4.1. Market Size And Forecast
5.4.2. Market Share Analysis, By Country
5.5. Mtor Inhibitors
5.5.1. Market Size And Forecast
5.5.2. Market Share Analysis, By Country
5.6. Other Immunosuppressants
5.6.1. Market Size And Forecast
5.6.2. Market Share Analysis, By Country
Chapter 6: Immunosuppressants Market, By Distribution Channel
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Hospital Pharmacies
6.2.1. Market Size And Forecast
6.2.2. Market Share Analysis, By Country
6.3. Retail Pharmacies
6.3.1. Market Size And Forecast
6.3.2. Market Share Analysis, By Country
6.4. Online Pharmacy
6.4.1. Market Size And Forecast
6.4.2. Market Share Analysis, By Country
Chapter 7: Immunosuppressant Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.3. Market Size And Forecast, By Indication
7.2.4. Market Size And Forecast, By Drug Class
7.2.5. Market Size And Forecast, By Distribution Channel
7.2.6. U.S.
7.2.6.1. U.S. Market Size And Forecast, By Indication
7.2.6.2. U.S. Market Size And Forecast, By Drug Class
7.2.6.3. U.S. Market Size And Forecast, By Distribution Channel
7.2.7. Canada
7.2.7.1. Canada Market Size And Forecast, By Indication
7.2.7.2. Canada Market Size And Forecast, By Drug Class
7.2.7.3. Canada Market Size And Forecast, By Distribution Channel
7.2.8. Mexico
7.2.8.1. Mexico Market Size And Forecast, By Indication
7.2.8.2. Mexico Market Size And Forecast, By Drug Class
7.2.8.3. Mexico Market Size And Forecast, By Distribution Channel
7.3. Europe
7.3.1. Key Growth Factors And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.3. Market Size And Forecast, By Indication
7.3.4. Market Size And Forecast, By Drug Class
7.3.5. Market Size And Forecast, By Distribution Channel
7.3.6. Germany
7.3.6.1. Germany Market Size And Forecast, By Indication
7.3.6.2. Germany Market Size And Forecast, By Drug Class
7.3.6.3. Germany Market Size And Forecast, By Distribution Channel
7.3.7. France
7.3.7.1. France Market Size And Forecast, By Indication
7.3.7.2. France Market Size And Forecast, By Drug Class
7.3.7.3. France Market Size And Forecast, By Distribution Channel
7.3.8. UK
7.3.8.1. UK Market Size And Forecast, By Indication
7.3.8.2. UK Market Size And Forecast, By Drug Class
7.3.8.3. UK Market Size And Forecast, By Distribution Channel
7.3.9. Italy
7.3.9.1. Italy Market Size And Forecast, By Indication
7.3.9.2. Italy Market Size And Forecast, By Drug Class
7.3.9.3. Italy Market Size And Forecast, By Distribution Channel
7.3.10. Rest of Europe
7.3.10.1. Rest of Europe Market Size And Forecast, By Indication
7.3.10.2. Rest of Europe Market Size And Forecast, By Drug Class
7.3.10.3. Rest of Europe Market Size And Forecast, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Growth Factors And Opportunities.
7.4.2. Market Size And Forecast, By Country
7.4.3. Market Size And Forecast, By Indication
7.4.4. Market Size And Forecast, By Drug Class
7.4.5. Market Size And Forecast, By Distribution Channel
7.4.6. Japan
7.4.6.1. Japan Market Size And Forecast, By Indication
7.4.6.2. Japan Market Size And Forecast, By Drug Class
7.4.6.3. Japan Market Size And Forecast, By Distribution Channel
7.4.7. China
7.4.7.1. China Market Size And Forecast, By Indication
7.4.7.2. China Market Size And Forecast, By Drug Class
7.4.7.3. China Market Size And Forecast, By Distribution Channel
7.4.8. India
7.4.8.1. India Market Size And Forecast, By Indication
7.4.8.2. India Market Size And Forecast, By Drug Class
7.4.8.3. India Market Size And Forecast, By Distribution Channel
7.4.9. Australia
7.4.9.1. Australia Market Size And Forecast By Indication
7.4.9.2. Australia Market Size And Forecast, By Drug Class
7.4.9.3. Australia Market Size And Forecast, By Distribution Channel
7.4.10. Rest of Asia-Pacific
7.4.10.1. Rest of Asia-Pacific Market Size And Forecast By Indication
7.4.10.2. Rest of Asia-Pacific Market Size And Forecast, By Drug Class
7.4.10.3. Rest of Asia-Pacific Market Size And Forecast, By Distribution Channel
7.5. LAMEA
7.5.1. Key Growth Factors And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.3. Market Size And Forecast, By Indication
7.5.4. Market Size And Forecast, By Drug Class
7.5.5. Market Size And Forecast, By Distribution Channel
7.5.6. Brazil
7.5.6.1. Brazil Market Size And Forecast, By Indication
7.5.6.2. Brazil Market Size And Forecast, By Drug Class
7.5.6.3. Brazil Market Size And Forecast, By Distribution Channel
7.5.7. Saudi Arabia
7.5.7.1. Saudi Arabia Market Size And Forecast, By Indication
7.5.7.2. Saudi Arabia Market Size And Forecast, By Drug Class
7.5.7.3. Saudi Arabia Market Size And Forecast, By Distribution Channel
7.5.8. South Africa
7.5.8.1. South Africa Market Size And Forecast, By Indication
7.5.8.2. South Africa Market Size And Forecast, By Drug Class
7.5.8.3. South Africa Market Size And Forecast, By Distribution Channel
7.5.9. Rest of LAMEA
7.5.9.1. Rest of LAMEA Market Size And Forecast, By Indication
7.5.9.2. Rest of LAMEA Market Size And Forecast, By Drug Class
7.5.9.3. Rest of LAMEA Market Size And Forecast, By Distribution Channel
Chapter 8: Company Profiles
8.1. Abbvie Inc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves And Developments
8.2. Astellas Pharma Inc.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.3. Bristol-Myers Squibb Company
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.3.6. Key Strategic Moves And Developments
8.4. Glaxosmithkline Plc.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.4.6. Key Strategic Moves And Developments
8.5. Intas Pharmaceuticals Ltd. (Accord Healthcare Ltd.)
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.6. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments
8.7. Mylan N.V.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.7.6. Key Strategic Moves And Developments
8.8. Novartis International Ag (Sandoz)
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves And Developments
8.9. Pfizer Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.9.6. Key Strategic Moves And Developments
8.10. Sanofi S.A.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves And Developments
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Bristol Myers Squibb
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • Mylan Laboratories Inc.
According to the report, titled, 'Immunosuppressant Market by Drug Class, Indication, And Distribution Channels: Global opportunity Analysis and Industry Forecast, 2019-2026,' the global immunosuppressant market size is expected to reach $42,511.37 million by 2026, registering a CAGR of 14.7% from 2019 to 2026, in terms of value.

The global immunosuppressants market size was valued at $13,890 million in 2018 and is expected to reach $42,511 million by 2026, registering a CAGR of 14.7% from 2019 to 2026. Immunosuppressants are the drugs that are administered to minimize the chances of organ rejection after transplantation. For almost every individual who receives an organ transplant, immunosuppressants are a must to be taken. This is because immune system reacts to transplanted organs as foreign objects and develops an immune response against it, thereby, destroying the organ and at the same time affect other body parts as well. These drugs prevent hyper immune response of a patient’s body. These drugs are also widely used by patients suffering from auto-immune disorders such as Chron’s disease, irritable bowel disease, and arthritis.

Significant increase in the incidence of autoimmune disorders including arthritis and multiple sclerosis and rise in adoption of organ donation among individuals are the major factors that drive the immunosuppressant market growth. In addition, surge in government initiatives towards developing programmes for raising awareness related o organ transplantation propels the market growth. For instance, according to European National Health Service (NHS) in 2018, the U.K. government announced the introduction of new plans to change the law for organ and tissue donation to address urgent unmet need for organs within Indian-origin communities in the country. However, high cost of immunosuppressant drugs and side effects associated with them such as diarrhoea, higher susceptibility to infection, nausea, and vomiting are expected to hamper the growth of immunosuppressants market. On the contrary, the increase in use of tissue engineering for generation of implants provides growth opportunities to the immunosuppressant market trends. In addition, rise in disposable income in developing economies and surge in awareness among individuals toward organ donation is anticipated to create lucrative opportunities in the near future.

By drug class, the calcineurin inhibitors segment accounted for majority of the immunosuppressants market share in 2018 and is expected to exhibit a prominent growth rate in the near future, owing to the fact that it is the most used immunosuppressant drug used after organ transplantation to suppress hyper immune response. The most widely prescribed calcineurin inhibitors drugs include cyclosporine and tacrolimus. This segment is also anticipated to be the fastest growing drug class segment during the forecast period.

By indication, the auto-immune disorder segment dominated the immunosuppressants market in 2018, and is anticipated to maintain its dominance during the forecast period. This is attributed to the surge incidence of auto immune disorders across the globe. For instance, according to national institute of environmental health sciences (NIH), autoimmune diseases are among the most prevalent diseases in the U.S., affecting more than 23.5 million Americans.

Key Findings of the Study
By drug class, the calcineurin inhibitors segment accounted for the highest market share of 35% in 2018 and is anticipated to grow at the fastest rate during the forecast period.
By region, North America was the major shareholder and accounted for the highest share of 42% in 2018.
By indication, auto-immune disorder segment is expected to grow at a CAGR of 13.6% during the forecast period.
By distribution channel, the hospital pharmacy segment dominated the market in 2018 and is anticipated to maintain its dominance during the forecast period.

Comprehensive competitive analysis and profiles of major market players such as Astellas Pharma, Inc., Bristol Myers Squibb, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Mylan Laboratories Inc., Novartis AG, Pfizer, Inc., Sanofi S.A. are provided in this report.
Note: Product cover images may vary from those shown
  • Astellas Pharma Inc.
  • Bristol Myers Squibb
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mylan Laboratories Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...